Tag Archive for: biotechnology

Link Biologics strengthens Board with drug discovery expert Dr Niall Martin to advance its TSG-6-based therapeutic pipeline

/in

Dr Martin brings over two decades of leadership in translational science, drug discovery and biotech strategy and entrepreneurship Strengthens Link’s position as it advances its proprietary TSG-6-based therapeutic pipeline towards the clinic  London, UK – 24 February 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies, that have a unique […]

Read more

AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform

/in

AmacaThera receives US$5 million upfront and up to US$225 million in potential future milestone payments with Pacira BioSciences for AMT-143, AmacaThera’s long-acting non-opioid anesthetic for post-operative pain AMT-143 leverages AmacaThera’s breakthrough tunable hydrogel platform, delivering sustained local release of ropivacaine AmacaThera and Pacira will collaborate on the Phase 2 clinical program, and Pacira will fund […]

Read more

Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

/in

Highly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution. Accomplished Chief Business Officer will drive business development and partnering deals. Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study. Edinburgh and London, UK 10 September 2025 – Resolution Therapeutics (“Resolution” or “Company”), a clinical-stage biopharmaceutical […]

Read more

AMSilk strengthens management team with key hires of Ralph Fraundorfer and Ctibor Kohutovic to Management Board

/in

Neuried, Germany, 23 April 2024: AMSilk GmbH (“AMSilk”), a global leader in advanced materials made from spider silk-based proteins, today announces the appointments of Ralph Fraundorfer and Ctibor Kohutovic to its Management Board starting immediately. Read more…

Read more

Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma

/in

Berlin, Germany, 10th January 2024 – Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces it has submitted an application with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to undertake a Phase 1 trial of 123I-ATT001, its Iodine-123 labelled PARP inhibitor in patients with recurrent […]

Read more